Today's Rundown GlaxoSmithKline’s big R&D idea? Focusing on the immune system, as Barron injects new philosophy GlaxoSmithKline makes $300M investment in 23andMe, forms 50-50 R&D pact resTORbio surges as midstage data set up phase 3 for drug to prevent RTIs in the elderly [Sponsored] Q&A with Cardinal Health Regulatory Sciences: Navigating cell and gene therapies through clinical and regulatory hurdles Alector raises $133M in 5th VC round to push neuro-immunology drugs into Alzheimer’s trials Canadian cannabinoid biotech Inversago looks to the clinic Illumina scientist’s startup aims to rapidly detect drug resistance in bacterial DNA Featured Story | | | Wednesday, July 25, 2018 GlaxoSmithKline didn’t have much in the way of R&D news during their last quarterly update, but the company told analysts to watch that space during the second quarter, as some big research news was in the offing. |
|
|
| This week's sponsor is FierceBiotech. | | | |
Top Stories Wednesday, July 25, 2018 GlaxoSmithKline has made a $300 million equity investment in 23andMe as part of a deal that pulls it close to the consumer genetics pioneer. The partners are contributing preclinical programs to a 50-50 collaboration that will use 23andMe’s genotypic and phenotypic data to accelerate progress. Wednesday, July 25, 2018 Armed with positive phase 2b data, resTORbio is hoping to start pivotal trials next year for its lead drug to prevent respiratory tract infections in the elderly. Monday, July 23, 2018 Gene and cell therapies are at the cutting-edge of biomedical research, promising potentially curative options for a host of disorders such as forms of blindness, blood cancers and inherited diseases. Wednesday, July 25, 2018 Previous Fierce 15 winner Alector has raised $133 million through a fifth round of venture capital financing, with plans to move at least three of its immune-modulating drugs into clinical testing against neurodegenerative disorders within the next year, including in Alzheimer’s disease and dementia. Wednesday, July 25, 2018 Inversago Pharma reeled in a $7 million series A to move a suite of next-generation cannabinoid receptor-1 blockers into the clinic. It is working on treatments for Prader-Willi syndrome, as well as metabolic disorders including diabetes. Wednesday, July 25, 2018 One of the founding scientists of Illumina has come out with a new gene-sequencing software startup that aims to tackle antimicrobial resistance. | This week's sponsor is IQVIA. | | | |
Resources Sponsored by: Veeva Ready to modernize your RIM environment? Secure buy-in with these tips. Sponsored by: Medidata Accelerate Clinical Research as Study Complexity Grows Sponsored by: Patheon, part of Thermo Fisher Scientific Biologics, orphan drugs, and precision medicine are on the rise, and that means some big changes for drug development and manufacturing companies. What should pharma companies look for when navigating this new era of small-volume manufacturing? Here are some ideas to consider when developing a new manufacturing strategy. Sponsored by: Veeva See results from the Tufts eClinical Landscape Study – CRO Report on current data management practices, goals, and challenges for contract research organizations (CROs). Sponsored by: Docusign Life science companies are experiencing a significant transformation in how they bring new products to market. Drug Approval, Manufacturing Quality & Regulation 2018 | Online The Life Science Women's Conference August 8-9, 2018 | Austin, Texas Join 200+ Service and Support Leaders at Field Service Amelia Island this August August 27-29, 2018 | Amelia Island, FL BIO Latin America 2018 September 4-5, 2018 | São Paulo, Brazil RESI HealthTech Week September 5-7, 2018 | Boston, MA 2018 Latin America Healthcare Compliance Certification Program Sao Paulo, Brazil | Sep 24-27, 2018 4th Annual Bio/Pharmaceutical Product Launch Summit September 25-26, 2018 | Cambridge, MA Drug Development Immersion September 26-27, 2018 | West Windsor, NJ FierceBiotech 3rd Drug Development Forum October 1–3, 2018 | Hilton Boston Logan Airport Hotel | Boston, MA The Advanced Biologic Development Summit at Northeastern University October 9, 2018 | Boston, MA BioImmersion: Biotech for the Non-Scientist October 16-18, 2018 | Chicago, IL FierceBiotech Executive Summit: London October 30, 2018 | Royal Society of Medicine Drug Development Boot Camp® 2018 – Register Now! November 14-15, 2018 | Boston, MA | Register now and start your pre-Boot Camp preparation | 